DR. ANISA HASSAN M.D.
Prescription History 1164537643
Internal Medicine - Hematology & Oncology in Joplin, MO


Quality Rating: 64.74 out of 100 score

NPI Status: Active since August 21, 2006

Contact Information

3315 MCINTOSH CIR
JOPLIN, MO
ZIP 64804
Phone: (417) 347-4000
Fax: (417) 347-4064

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ANISA HASSAN M.D., an active Hematology & Oncology specialist practicing in Joplin, MO. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 103 documented patient claims. Among these therapy options, the most frequently utilized medication is Xarelto, which accounts for 22 claims alone.

Medication Index

No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 57.0
Days Supply 1,710
MO State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills157.6
Peer Average Days Supply4,679
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.6% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $413.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.74

State Avg Cost Per Claim

$24.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
MO State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.7
Peer Average Days Supply411
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 46.2% more claims than the standard regional baseline profile for MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $304,662.21 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,034.85

State Avg Cost Per Claim

$14,358.80

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Exemestane

Generic Formulation: ExemestaneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 22.0
Days Supply 660
MO State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills58.9
Peer Average Days Supply1,747
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.4% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $964.45 across this reporting matrix range.

Provider Avg Cost Per Claim

$74.19

State Avg Cost Per Claim

$208.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Letrozole

Generic Formulation: LetrozoleSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 54.0
Days Supply 1,620
MO State Average Benchmarks
Peer Average Claims52.0
Peer Average 30-Day Fills110.9
Peer Average Days Supply3,296
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 65.4% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $665.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$36.96

State Avg Cost Per Claim

$30.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Potassium Chloride

Generic Formulation: Potassium ChlorideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.8
Days Supply 384
MO State Average Benchmarks
Peer Average Claims93.0
Peer Average 30-Day Fills158.7
Peer Average Days Supply4,484
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 87.1% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $618.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.52

State Avg Cost Per Claim

$27.09

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.

Therapeutic Applications

This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. A normal level of potassium in the blood is important. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Most people get enough potassium by eating a well-balanced diet. Some conditions that can lower your body's potassium level include severe prolonged diarrhea and vomiting, hormone problems such as hyperaldosteronism, or treatment with water pills/diuretics.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 643
MO State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills80.8
Peer Average Days Supply2,241
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.9% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,063.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$593.77

State Avg Cost Per Claim

$794.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ANISA HASSAN M.D. provides transparency into local medical care patterns within Joplin, MO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.